| 000 | 01776 a2200493 4500 | ||
|---|---|---|---|
| 005 | 20250515083610.0 | ||
| 264 | 0 | _c20080513 | |
| 008 | 200805s 0 0 eng d | ||
| 022 | _a0302-2838 | ||
| 024 | 7 |
_a10.1016/j.eururo.2007.08.039 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aGamé, Xavier | |
| 245 | 0 | 0 |
_aBotulinum toxin A detrusor injections in patients with neurogenic detrusor overactivity significantly decrease the incidence of symptomatic urinary tract infections. _h[electronic resource] |
| 260 |
_bEuropean urology _cMar 2008 |
||
| 300 |
_a613-8 p. _bdigital |
||
| 500 | _aPublication Type: Clinical Trial; Comparative Study; Journal Article | ||
| 650 | 0 | 4 | _aAdult |
| 650 | 0 | 4 |
_aBotulinum Toxins, Type A _xadministration & dosage |
| 650 | 0 | 4 | _aCystoscopy |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 | _aFollow-Up Studies |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aIncidence |
| 650 | 0 | 4 | _aInjections, Intramuscular |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 |
_aMuscle Contraction _xdrug effects |
| 650 | 0 | 4 |
_aNeuromuscular Agents _xadministration & dosage |
| 650 | 0 | 4 | _aProspective Studies |
| 650 | 0 | 4 | _aTime Factors |
| 650 | 0 | 4 | _aTreatment Outcome |
| 650 | 0 | 4 |
_aUrinary Bladder _xdrug effects |
| 650 | 0 | 4 |
_aUrinary Bladder, Neurogenic _xcomplications |
| 650 | 0 | 4 |
_aUrinary Tract Infections _xepidemiology |
| 650 | 0 | 4 |
_aUrodynamics _xdrug effects |
| 700 | 1 | _aCastel-Lacanal, Evelyne | |
| 700 | 1 | _aBentaleb, Youssef | |
| 700 | 1 | _aThiry-Escudié, Isabelle | |
| 700 | 1 | _aDe Boissezon, Xavier | |
| 700 | 1 | _aMalavaud, Bernard | |
| 700 | 1 | _aMarque, Philippe | |
| 700 | 1 | _aRischmann, Pascal | |
| 773 | 0 |
_tEuropean urology _gvol. 53 _gno. 3 _gp. 613-8 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1016/j.eururo.2007.08.039 _zAvailable from publisher's website |
| 999 |
_c17332847 _d17332847 |
||